NCT00294736View on ClinicalTrials.gov

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
NSCLC
Interventions
DRUG

Tarceva

Dose Escalation: 150-350+ mg/day

Trial Locations (9)

27157

Wake Forest University Comprehensive Cancer Center, Winston-Salem

93309

Comprehensive Blood and Cancer Center, Bakersfield

EH4 2XU

University of Edinburgh,Division of Oncology,, Edinburgh

AB25 2ZN

Aberdeen Royal Infirmary, Aberdeen

DD1 9SY

Ninewells Hospital, Dundee

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

NE7 7DH

Sir Bobby Robson Cancer Trials Research Centre, Newcastle upon Tyne

S10 2SJ

Department of Oncology, Sheffield

SM2 5PT

Royal Marsden Hospital, Sutton

Sponsors
All Listed Sponsors
lead

OSI Pharmaceuticals

INDUSTRY

NCT00294736 - A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens | Biotech Hunter | Biotech Hunter